ArticleNature communications2021
Mismatch repair deficiency predicts response to HER2 blockade in HER2-negative breast cancer.
Registry-linked trialOpen access · goldAbstract read
In one paragraph
Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07729046 (Neu Direction), which is not on this map. Cited by 14 papers.
0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
NCT07729046 phase2not yet recruitingnot on this mapstarted 2027, after this paper: background citation
Neu Direction: A Single Center Phase II Randomized Clinical Trial to Assess the Efficacy of Adding HER Inhibition to Standard of Care in Patients With Metastatic MLH1-low Endocrine-resistant ER+/HER2- Breast Cancer
Who cites it
14 citing papers in PubMed, 23 citations in OpenAlex.
- Modulation of the Estrogen/erbB2 Receptors Cross-talk by CDK4/6 Inhibition Triggers Sustained Senescence in Estrogen Receptor- and ErbB2-positive Breast Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Trial
- Aberrant cytoplasmic localization of MLH1 characterizes a cell population that seeds breast cancer recurrence.Nature communications · 2025Article
- Advances in diagnostic and therapeutic applications of mismatch repair loss in cancer.DNA repair · 2025Review
- Case Report: A patient with lynch syndrome with vaginal endometriosis-associated malignancy and synchronous colonic tubulovillous adenoma.Frontiers in medicine · 2025Article
- Nonrepair functions of DNA mismatch repair proteins: new avenues for precision oncology.Trends in cancer · 2025Review
- LATS2 and FAT4 as key candidate genes of hippo pathway associated with the risk and progression of breast cancer: an in-silico approach.Scientific reports · 2024Article
- Low and Ultra-Low HER2 in Human Breast Cancer: An Effort to Define New Neoplastic Subtypes.International journal of molecular sciences · 2023Review
- Molecular portraits of cell cycle checkpoint kinases in cancer evolution, progression, and treatment responsiveness.Science advances · 2023Article
- The impact of HER2-low status on response to neoadjuvant chemotherapy in clinically HER2-negative breast cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023Article
- HER2-Low Breast Cancer: Current Landscape and Future Prospects.Breast cancer (Dove Medical Press) · 2023Review
- Poziotinib Inhibits HER2-Mutant-Driven Therapeutic Resistance and Multiorgan Metastasis in Breast Cancer.Cancer research · 2022Article
- Editorial: Diagnosis and Treatment of Breast Cancer in 2022: The Rise of Novel Molecular Biomarkers.Frontiers in molecular biosciences · 2022Article
- HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer.Frontiers in molecular biosciences · 2022Review
- Commentary: Mismatch Repair Deficiency and Microsatellite Instability in Triple-Negative Breast Cancer: A Retrospective Study of 440 Patients.Frontiers in oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Nindo B PunturiTumor Microenvironment and Cancer Immunology, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.
Sinem SekerTumor Microenvironment and Cancer Immunology, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.
Vaishnavi DevarakondaLester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, USA.
Aloran MazumderTumor Microenvironment and Cancer Immunology, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.
Rashi KalraLester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, USA.
Ching Hui ChenLester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, USA.ORCID 0000-0002-8365-3036
Shunqiang LiDepartment of Medicine, Washington University in St. Louis, St. Louis, MO, USA.
Tina PrimeauDepartment of Medicine, Washington University in St. Louis, St. Louis, MO, USA.
Matthew J EllisLester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, USA.
Shyam M KavuriLester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, USA. kavuri@bcm.edu.ORCID 0000-0002-3321-6727
Svasti HaricharanTumor Microenvironment and Cancer Immunology, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA. sharicharan@sbpdiscovery.org.ORCID 0000-0002-4471-8853
Baylor College of Medicine · USSanford Burnham Prebys Medical Discovery Institute · USWashington University in St. Louis · US
Funding
Member Site CoreU10CA180821 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI Evanthia Galanis · 2014 to 2026
$177.3MStatistics CoreU10CA180882 · NCI · MAYO CLINIC ROCHESTER · PI Sumithra Jay Mandrekar · 2014 to 2026
$115.0MTumor Microenvironment and Cancer ImmunologyP30CA030199 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI Michael Jackson · 1985 to 2026
$107.2MTumor BiologyP30CA125123 · NCI · BAYLOR COLLEGE OF MEDICINE · PI DAVID R ROWLEY · 2007 to 2026
$73.9MTranslational Research in Breast Cancer (SPORE)P50CA186784 · NCI · BAYLOR COLLEGE OF MEDICINE · PI Xiang Zhang · 2014 to 2026
$24.5MA pan-cancer role for MutL loss in inducing treatment resistanceK22CA229613 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI HARICHARAN, SVASTI · 2018 to 2020
$442kNCI NIH HHS K22 CA229613NCI NIH HHS P30 CA030199NCI NIH HHS P30 CA125123NCI NIH HHS P50 CA186784NCI NIH HHS U10 CA180821NCI NIH HHS U10 CA180882
Abstract
Resistance to endocrine treatment occurs in ~30% of ER
Indexed as
DNA Mismatch RepairAnimalsBreast NeoplasmsCell Line, TumorDrug Resistance, NeoplasmErb-b2 Receptor Tyrosine KinasesFemaleGene Knockdown TechniquesHumansMCF-7 CellsMiceMice, NudeMice, SCIDMutL Protein Homolog 1MutL ProteinsProteinsERBB2 protein, humanErb-b2 Receptor Tyrosine Kinaseslysosomal proteinsMLH1 protein, humanMutL Protein Homolog 1MutL ProteinsProteinsReceptors, EstrogenRNA, Messenger
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
NCT07729046ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.